用链脲佐菌素、洛莫司汀（环己亚硝脲）、阿霉素和博来霉素联合治疗（SCAB方案）的晚期霍奇金病患者的长期随访
Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB).
作者信息
Wiernik P H, Schiffer C A
机构信息
Albert Einstein Cancer Centers, New York, NY 10467.
出版信息
J Cancer Res Clin Oncol. 1988;114(1):105-7. doi: 10.1007/BF00390494.
The 11 year disease-free and overall survival for 20 previously untreated patients with Hodgkin's disease stages IIIB (10 patients), IVA (2 patients), and IVB (8 patients) treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin, and bleomycin are presented. The complete response rate was 80% and the median duration of complete remission is 8.6 + years, with a range of 0.5 to 11.0 + years. These results may be better than those obtained with mustine, vincristine, procarbazine, and prednisolone (MOPP) of MOPP alternating with doxorubicin, bleomycin, vinblastine, and docarbazine (ABVD). The results of this small study need to be confirmed by a larger one.
本文报告了20例未经治疗的霍奇金病患者的11年无病生存率和总生存率，这些患者处于IIIB期（10例）、IVA期（2例）和IVB期（8例），接受了链脲佐菌素、洛莫司汀（环己亚硝脲）、阿霉素和博来霉素联合治疗。完全缓解率为80%，完全缓解的中位持续时间为8.6年以上，范围为0.5至11.0年以上。这些结果可能优于使用氮芥、长春新碱、丙卡巴肼和泼尼松（MOPP）或MOPP与阿霉素、博来霉素、长春花碱和达卡巴嗪交替使用（ABVD）所获得的结果。这项小型研究的结果需要更大规模的研究来证实。
Zotero 插件